Correction to: Nature Biomedical Engineering https://doi.org/10.1038/s41551-018-0284-0, published online 17 September 2018.
The authors wish to add the following sentence into the ‘Competing interests’ section of this Article: “P.W.K. has investment interest in Context Therapeutics LLC, DRGT, Placon, Seer Biosciences and Tarveda Therapeutics, is a company board member for Context Therapeutics LLC, is a consultant and scientific advisory board member for BIND Biosciences, Inc., BN Immunotherapeutics, DRGT, GE Healthcare, Janssen, Metamark, New England Research Institutes, Inc., OncoCellMDX, Progenity, Sanofi, Seer Biosciences, Tarveda Therapeutics and Thermo Fisher, and serves on data safety monitoring boards for Genentech/Roche and Merck.” This has now been included.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Islam, M.A., Xu, Y., Tao, W. et al. Author Correction: Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat Biomed Eng 2, 968 (2018). https://doi.org/10.1038/s41551-018-0331-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41551-018-0331-x
This article is cited by
-
mRNA-based therapeutics: powerful and versatile tools to combat diseases
Signal Transduction and Targeted Therapy (2022)